25 August 2017Pharma

Video interview: Regulatory issues key for life sciences in Brexit debate

With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
20 November 2026   A US patent board finds two Halozyme patents unpatentable, while a German appeals court overturns an injunction blocking the subcutaneous version of Keytruda, marking two setbacks for Halozyme in its ongoing dispute with the pharma giant.
Pharma
18 November 2026   A heated dispute over Boehringer’s diabetes drug empagliflozin has ended in a split decision, with the judge drawing a sharp line between what a patent discloses and what can be inferred from it.
Pharma
12 November 2026   Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.